Salvage therapy with bicalutamide 80mg in patients with PSA failure under medical or surgical castration for prostate cancer

16010 Background: Previous American studies reported modest effects of deferred use of bicalutamide 150mg in patients with hormone refractory prostate cancer (HRPC) during androgen deprivation monotherapy (ADMT). The objective of the current study was to evaluate the potential benefit of sequential introduction of bicalutamide 80mg therapy in Japanese patients with rising PSA under definitive LHRH agonist therapy or surgical castration for prostate cancer. Methods: Forty-seven patients with HRPC during ADMT were treated with deferred combined androgen blockade (CAB) therapy, administering bicalutamide 80mg once-daily. HRPC was defined biochemically as three consecutive rises in PSA levels during ADMT. The treatment response was defined as a 50% or greater decline in PSA levels. Prognostic values of various pretreatment parameters for responsiveness to deferred CAB were statistically determined. When the disease relapsed during deferred CAB, bicalutamide was discontinued and the patients were evaluated for...